Acute repetitive seizures (ARS) is known as recurrent, serial, or cluster seizures. It is a phenomenon in treatment-refractory epilepsy that is distinguished by a close chronological connection of seizures that surpass a patient’s typical baseline seizure occurrence. ARS poses a risk of hospitalization and/or evolution into status epilepticus, a life-threatening seizure emergency, which underscores the need for early, effective management. Benzodiazepines are usually used as needed for rescue treatment in this orphan indication, being prescribed adjunctively to patients’ chronic antiepileptic drug (AED) regimen and administered on an as-needed basis.
Growth of this market is highly attracted to including growing prevalence of neurological diseases and strong pipeline products and increasing number of regulatory approval. Moreover, growing investment on research and development is expected to offer dynamic growth opportunities as major branded drugs are in pipeline phase and are likely to be introduced in the market very soon with help of robust research and development projects. Shifting consumer base from rectal to nasal route of administration is anticipated to offer growth opportunities. However, lack of awareness towards seizures is one of the major treatment challenges in some of the countries of Asia-Pacific including India. This problem is further exaggerated due to poor accessibility of adequate health care provision, lack of affordable treatment, availability of specialist care, distance to health care facilities, and obtainability of pharmacological treatment. Moreover, the population in such countries is unaware about new treatments in neurological disorders. On the other hand, with an increase in the demand for safe alternative and cost-effective alternatives have led to the emergence of clinical studies for evaluating the safety and effectiveness of nasal route of administration in the form of nasal sprays
The market research study on “Acute Repetitive Seizures Market (By Product: USL-261, NRL-1, AZ-002, Diastat Rectal Gel, Others ) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026” offers a detailed insights on the global acute repetitive seizures market entailing insights on its different market segments. Market dynamics with drivers, restraints and opportunities with their impact are provided in the report. The report provides insights on global acute repetitive seizures market, its type, application, and major geographic regions. The report covers basic development policies and layouts of technology development processes. Secondly, the report covers global acute repetitive seizures market size and volume, and segment markets by type, application, and geography along with the information on companies operating in the market. The acute repetitive seizures market analysis is provided for major regional markets including North America, Europe, Asia-Pacific, Middle East, Latin America, Africa. For each region, the market size and volume for different segments has been covered under the scope of report. The players profiled in the report include Grupo Ferrer Internacional S.A. (ALEXZA), Neurelis, Inc., UCB S.A., and more.
Key players investigating the use of nasal sprays are anticipated to lead to successful outcomes which further created opportunities for the use of oral to rectal route of administration. Some of investigational products are anticipated to be launched in near future accelerated by increase in the number of FDA approvals and geographical expansion by market players.
The global Acute Repetitive Seizures market is segmented as below:
Market By Product
Market By Geography